WA-SPIE
SPIE, the international society for optics and photonics, held an impactful and vibrant Photonics West last week at San Francisco’s Moscone Center, with 24,000-plus technical professionals registered from more than 70 countries across the international optics and photonics community. The largest annual photonics conference, which ran from 27 January to 1 February, hosted over 1,500 exhibitors, and featured over 5,000 technical presentations across an interactive and engaging week that included BiOS, LASE, OPTO, Quantum West, the BiOS Expo, the Photonics West exhibition, the Quantum West Expo, and the co-located AR|VR|MR conference and exhibition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208158413/en/
SPIE Photonics West 2024 hosted an enthusiastic crowd of optics and photonics professionals at San Francisco's Moscone Center. (Photo: Business Wire)
“Photonics West heralds the beginning of the optics and photonics calendar each year for good reason,” said SPIE CEO Kent Rochford. “The invigorating energy and high levels of enthusiasm throughout the Moscone Center characterized a truly exciting week. AR|VR|MR continues to grow by leaps and bounds, and the addition of a standalone exhibit to the Quantum West program reflects the growing impact of the technology. We were also delighted by the success of our brand-new SPIE Global Business Forum, a packed event that drew top industry executives together for high-level presentations and conversation. Altogether it was a pleasure to be part of the networking, research-sharing, and collaborative discussions among world-leading scientists, engineers, students, and businesspeople and I’m already looking forward to Photonics West 2025.”
As always, the dynamic week showcased the latest innovative technologies and discoveries stemming from a diverse and thriving optics and photonics community, bringing together researchers, innovators, engineers, entrepreneurs, and business leaders from across the globe. Over 100 distinct technical conferences paired perfectly with the four exhibitions held during the week, bringing researchers and companies together to further science, technology, and applications. The week also included a wide range of live product demonstrations on the exhibition floors as well as a job fair.
The inaugural SPIE Global Business Forum was a resounding, sold-out success. With the 16th annual Prism Awards honoring the top new optics and photonics products, and the fast-paced Startup Challenge pitch competition, SPIE Photonics West recognized the best optics and photonics technologies, trends, and entrepreneurial opportunities, while the Quantum West Business Summit featured talks and panels that provided key insights into that expanding commercial ecosystem.
In addition, a program of 56 educational courses offered expert-led technical training and learning, which complemented the dozens of professional development and networking sessions. From Lunch and Learn programming focused on EDI, to networking and social events that provided many opportunities for in-person conversations and possible future collaborations, Photonics West featured a packed calendar of special events.
While the week held myriad opportunities for attendees to learn, network, and share their latest advancements, it was the buzzing exhibitions that best showcased the increasingly vital photonics industry and the importance of in-person meetings.
“The Global Business Forum made it clear that the optics and photonics industry is in the midst of a remarkable era of growth and innovation,” said Stratos Kehayas, PhD, Chief Product & Technology Officer, G&H. “The industry's collective enthusiasm at Photonics West underscores the pivotal role this trade show plays in driving collaboration, fostering innovation, and shaping the future.”
"This has been arguably one of the most productive Photonics Wests we've had in the last five years,” said nLIGHT Vice President and General Manager, Semiconductor Lasers, Matthew Randall. “It’s been very engaging, with lots of people coming through, and we're seeing new things at our booth and at other booths that make this particular show a positive experience. We are definitely seeing way more innovation now than in the last couple of years and that's been incredibly positive not only for nLIGHT, but for the entire photonics industry.”
“The week has been very good,” said MKS Instruments Senior Director of Marketing, Photonics Solutions Division, Vincent M. Issier. “The traffic has been very high and the attendance is incredible this year, and we are very happy with the level of engagement from people here.”
“The week has been great,” said IPG Photonics Director of Product Management, Beam Delivery, UV, Green & Ultrafast Lasers, Mustafa Coskun. “There was nice traffic coming through and it was really nice to connect with colleagues as well as our customers and other visitors. And this is what we're here for: to listen to our customers and understand what their problems are and how we can help them. This Photonics West has been great.”
“This year we were quite busy, even just walking around the show with so many people we know here and so many companies we are in touch with,” said TNO Business Consultant, Optics Manufacturing, Bart Snijders. “It’s great to see them all again. We’ve enjoyed being busy on the floor, busy with meetings. I would always like the show to be six or nine days long, because time is always too short for me here.”
During the Photonics West week, SPIE also announced its latest partnership – this one with The University of Manchester – in the SPIE Endowment Matching Program.
SPIE Photonics West 2025 will take place 25-30 January at the Moscone Center in San Francisco. The call for papers for the 2025 event will open in Spring of 2024.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $24 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208158413/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom